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Abstract
Two sensitive, selective, economic, and validated spectrofluorimetric methods were developed for the
determination of ebastine (EBS) in pharmaceutical preparations depending on reaction with its tertiary amino
group. Method I involves condensation of the drug with mixed anhydrides (citric and acetic anhydrides) producing
a product with intense fluorescence, which was measured at 496 nm after excitation at 388 nm.
Method (IIA) describes quantitative fluorescence quenching of eosin upon addition of the studied drug where the
decrease in the fluorescence intensity was directly proportional to the concentration of ebastine; the fluorescence
quenching was measured at 553 nm after excitation at 457 nm. This method was extended to (Method IIB) to
apply first and second derivative synchronous spectrofluorimetric method (FDSFS & SDSFS) for the simultaneous
analysis of EBS in presence of its alkaline, acidic, and UV degradation products.
The proposed methods were successfully applied for the determination of the studied compound in its dosage
forms. The results obtained were in good agreement with those obtained by a comparison method. Both methods
were utilized to investigate the kinetics of the degradation of the drug.
Background
Ebastine;(4’- tert.-butyl - 4-[4-(diphenylmethoxy) - piper-
idino] butyrophenone (Figure 1), is a potent long acting
antihistaminic H1 receptor antagonist drugs [1]. Litera-
ture survey reveals that only high performance liquid
chromatography was used for the estimation of ebastine
in presence of its metabolites [2,3].
Although chromatographic methods offer a high
degree of specificity, yet they require large amount of
high purity organic solvents and generate high amount
of waste. Therefore, there is a need for an alternative
substitute to these techniques for the routine quality
control analysis of the concerned drug.
It is clear that there is a need for a method that is sen-
sitive enough to monitor the drug level after therapeutic
doses. Spectrofluorimetry by virtue of its high sensitivity
meets this requirement. The proposed methods have
some distinct advantages that render them promising
substitutes for HPLC methods.
A number of organic acid anhydrides are capable of
forming colored products with tertiary amines [4];
malonic, citric, and aconitic acids are representative
examples. Aconitic acid however was found to be unsa-
tisfactory as invariably a purple solution resulted on
heating to dissolve the acid [5]. Tramadol, acebutolol
and dothiepin were determined based on the condensa-
tion of the cited drugs with malonic and acetic acids [6]
where the colored products were suitable for spectro-
photometric and spectrofluorimetric measurements;
while citric/acetic anhydrides were used for the spectro-
photometric determination of nizatidine [7], and some
H1 receptor antagonists [8] namely; cetirizine, fexofena-
dine, loratadine and acrivastine. Mixed anhydrides were
also used for the colorimetric determination of epoxy-
amine formulations (resulting from the reaction of
bisphenol A diglycidyl ether and m-xylylenediamine) in
a mixture of primary and secondary amines [9].
In spectrofluorimetric methods, high sensitivity and
selectivity are generally expected. However, problems of
selectivity can occur in multi-component analysis because
of the overlap of their spectra that could be observed. Spe-
cificity is a particular problem in the determination of
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(SFS) has been found to have several advantages [10], such
as simple spectra, high selectivity, low interference, etc.
Because of its sharp, narrow spectrum, SFS serves as a
very simple, effective method of obtaining data for quanti-
tative determination in a single measurement [11]. It has
attracted the attention of many researchers and developed
rapidly since it was firstly proposed by LIoyd [12].
Synchronous fluorescence spectroscopy techniques are
classified according to different scanning modes of
monochromators into constant wavelength, variety
angle, and constant energy. At present, the constant
wavelength method, in which a constant difference
between the emission and excitation wavelengths is
maintained, is used most extensively. The combination
of SFS and derivative is more advantageous than differ-
entiation of the conventional direct spectrofluorimetry
in terms of sensitivity, because the amplitude of the
derivative signal is inversely proportional to the band-
width of the original spectrum [13].
Recently, derivative synchronous fluorometry (DSF) has
been utilized for the determination of different mixtures in
their co formulated dosage forms and biological fluids,
such as metacycline and oxytetracycline [14], aspirin with
caffeine [15] or aspirin with salicylic acid [16], diflunisal
and salicylic acid [17], carvedilol and ampicillin [18], oxy-
tetracycline in medicated premixes and feeds [19], cinnari-
zine with either domperidone or nicergoline [20,21],
sulpiride and mebeverine hydrochloride [22] and benzo[a]
pyrene in spiked fatty foods [23]. This technique was also
applied for the determination of some drugs in the pre-
sence of their degradation products as in the case where
sulpiride was determined in presence of its alkaline degra-
dation product [24].
Other techniques mentioned in the literature for the
determination of drugs in mixtures include: HPLC with
diode array detection exemplified by the determination of
colistin and tiamulin in liquid and solid medicated pre-
mixes [25], sulfamethazine and trimethoprim in liquid
feed premixes [26]. HPLC employing pre-column derivati-
zation was also applied as in the assay of colistin antibiotic
in feeds after fluorimetric derivatization with phthaldialde-
hyde and 2-mercaptoethanol [27]. Organic solvent
extraction or solid phase extraction followed by HPLC
were also used such as determination of tiamulin in swine
feeds [28] and sulfamethazine in milk [29] respectively.
Furthermore, various assay procedures were mentioned
for the determination of some drugs depending on the
fact that changes in their chemical environment will mod-
ify their native spectra and allow their determination in
mixtures, as illustrated by the high binding ability of oxyte-
tracycline with some divalent cations that causes changes
in its native fluorescence spectrum facilitating its determi-
nation in veterinary formulations [30].
The International Conference on Harmonization
(ICH) guidelines [31] entitled “stability testing of new
drug substances and products” requires that stress test-
ing be carried out to elucidate the inherent stability
characteristics of the active substance. Susceptibility to
alkaline, acidic, oxidative, and UV degradation are of
the required tests. The present work is capable of pre-
senting an efficient novel DSF method for the determi-
nation of EBS in the presence of its different
degradation products, and to study the results kineti-
cally so as to indicate that the method is a stability
indicating one.
Up till now neither direct nor synchronous spectro-
fluorimetry has been reported for the analysis of ebas-
tine alone or in presence of its degradation products.
Experimental
Apparatus
a) The fluorescence spectra and measurements were
recorded using a Perkin Elmer LS 45 Luminescence
Spectrometer equipped with a 150 W Xenon arc lamp. A
1 cm quartz cell was used. Derivative spectra were evalu-
ated using Fluorescence Data Manager (FLDM) software,
Perkin Elmer Buck i.e. FL WINLAB, version 400.02.
b) A Consort NV P901 pH meter
Materials and reagents
All reagents and solvents were of Analytical Reagent
grade.
1) Ebastine (EBS); of purity 99.94% was kindly pro-
vided by Meivo Pharmaceutical Company, Cairo, Egypt.
2) Pharmaceutical preparations:
*Bastab
® tablets (BN#112038), labeled to contain 20
mg ebastine/tablet, Meivo Pharmaceutical Company,
Cairo, Egypt.
*Evastine
® syrup (BN# 94634), labeled to contain 5 mg
ebastine/5 ml, Marcyrl Pharmaceutical Industries, El
Obour City, Egypt.
3) Citric acid anhydride (CAA) was prepared as super-
saturated solution by dissolving citric acid (Merck) in
acetic anhydride (Prolabo) with the aid of sonication [8]
4) Eosin (Riedel-DE-Haen AG seeize–Hannover) 1.5 ×
10
-3M aqueous solution.
O
N
O
Figure 1 Structural formula of ebastine.
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Page 2 of 145) Mcliavain buffers (pH ranging from 2-8) were pre-
pared by mixing specific volumes of disodium hydrogen
phosphate (0.2 M) and citric acid (0.2 M) [32].
6) Sodium hydroxide (0.1, 0.4 M solution), hydrochlo-
ric acid (0.1, 0.4 M solution), hydrogen peroxide (3% v/v
solution); (BDH, Poole,UK).
5) Methanol (Aldrich)
Standard solutions
Stock solutions were prepared by dissolving 100.0 mg of
EBS in methanol and further diluted with the same sol-
vent as appropriate. The standard solutions were stable
for 7 days when kept in refrigerator.
General Procedure
For method І
Aliquots of standard solutions covering the concentra-
tion range of 0.1-1.0 μg/ml for EBS were transferred
into a set of 10 ml screw capped test tubes, evaporated
to dryness in a boiling water bath, and cooled under tap
water. Then 5.5 ml of CAA reagent were added, and the
test tubes were screwed up and heated in a boiling
water bath for 35 minutes. The solutions were cooled
and transferred quantitatively to 10 ml volumetric flasks;
diluted to the mark with distilled water and mixed well.
The fluorescence intensity of the resulting solutions was
measured at 496 nm after excitation at 388 nm. A blank
experiment was prepared simultaneously for each mea-
surement. The corrected relative fluorescence intensity
was plotted versus the final concentration of the drug
(μg/ml) to get the calibration graph; alternatively, the
corresponding regression equation was derived.
For method IIA
To a set of 10 ml volumetric flasks, aliquots of ebastine
standard solutions over the concentration range of 0.1-
1.0 μg/ml were transferred, 1 ml of 1.5 × 10
-3Me o s i n
were added, followed by 2.5 ml of mcliavain buffer pH
2.2, the volume was completed to mark with distilled
water and mixed well. The quenching of eosin fluores-
cence intensity was measured at 553 nm after excitation
at 457 nm.
For method IIB
After following the procedures mentioned in method IIA,
The synchronous fluorescence spectra of the solutions
were recorded by scanning both monochromators at (Δ
l) = 100, 60 or 40 nm in presence of alkaline, acidic, or
UV degradation products respectively. A scan rate of 600
nm/min using 10 nm excitation and emission windows
was used. The first and second-derivative fluorescence
spectra of EBS were derived from the normal synchro-
nous spectra using FLDM software. For best resolution
and smoothing 99 points were used. The fluorescence
intensities of the first and second-derivative spectra were
estimated at 421 and 453 nm respectively when EBS was
determined in presence of its alkaline degradation pro-
duct. When the drug was estimated in presence of its
acidic degradation product the first and second-derivative
spectra were determined at 431 and 419 nm respectively.
On the other hand ebastine was determined at 437 nm
and 458 nm using first and second-derivative techniques
respectively. A blank experiment was performed simulta-
neously. The peak amplitude of either the first or the sec-
ond derivative technique was plotted versus final
concentration of the drug (μg/ml) to obtain the calibra-
tion graphs. Alternatively, the corresponding regression
equations were derived.
Procedure for determination of ebastine in presence of
its degradation products
Aliquot volumes of EBS standard stock solution (400 μg/
ml) were transferred into a series of 25 ml volumetric
flask to obtain a final concentration of 40 μg/ml; the
volume was completed with 0.1 M sodium hydroxide or
0.1 M hydrochloric acid to prepare the alkaline or acidic
degradation product respectively. The solutions were left
in a boiling water bath for 50 minutes (alkaline degrada-
tion) and for 30 minutes (acidic degradation). Regarding
the UV degradation, the methanolic solution of EBS was
exposed to Deuterium lamp in a cabinet distance of 15
cm for 9 hours. These time intervals were determined so
as to follow the ICH guidelines [31] accomplishing 30%
degradation of the studied drug. Aliquot volumes of the
degraded solutions were transferred to a series of 10 ml
volumetric flasks, neutralized with 0.1 M hydrochloric
acid or 0.1 M sodium hydroxide for alkaline and acidic
degradation respectively, and the steps described under
procedure for method IIB were followed.
T h ep e a ka m p l i t u d eo ft h ef i r s to rt h es e c o n dd e r i v a -
tive techniques were plotted versus the final concentra-
tion of the drug (μg/ml) to obtain the calibration
graphs. Alternatively, the corresponding regression
equations were derived
Procedure for tablets
Twenty tablets were weighed and pulverized. An accu-
rately weighed quantity of the powder equivalent to con-
tain 20 mg of EBS was transferred into a small conical
flask, extracted three successive times each with 30 ml
of methanol. The extract was filtered into 100 ml volu-
metric flask. The conical flask was washed with few mls
of methanol, transferred to the volumetric flask and
completed to mark with the same solvent. Aliquots cov-
ering the concentration range were transferred either
into 10 ml screw capped test tubes (method I) or to 10
ml volumetric flasks (method IIA and IIB). The steps
described under “General Procedures for method I,
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Page 3 of 14method IIA or method IIB” were followed. The nominal
content of the tablets was determined either from the
calibration graphs or from the corresponding regression
equations.
Procedure for syrup
Aliquot volumes equivalent to 5 mg of the studied drug
were transferred into a 25 ml volumetric flask, serial
dilution was performed with methanol to obtain the
working concentration range and the steps described
under “General Procedure for method I, method IIA or
method IIB” were followed. The nominal content of the
syrup was determined either from the calibration graph
or by using the corresponding regression equation.
Procedure for preparation of degradation products
For the kinetic study, 2.5 ml of EBS standard solution
(400 μg/ml) were transferred into a series of 25 ml volu-
metric flasks to obtain a final concentration of 40 μg/ml,
0.4 M sodium hydroxide or 0.4 M hydrochloric acid
were added for method I. Regarding method II, 0.1 M
hydrochloric acid or 0.1 M sodium hydroxide were
used. The solutions were left in a thermostatically con-
trolled water bath at different temperature settings
(50, 60, 70, 80°C) for a fixed time interval (10 minutes).
Aliquot volumes of the degraded solutions were trans-
ferred to a series of 10 ml screw capped test tubes
(method I) and neutralized with 0.4 M hydrochloric acid
or 0.4 M sodium hydroxide for alkaline and acidic
degradation respectively, alternatively the degraded solu-
tions were transferred to 10 ml volumetric flasks
(method II) and neutralized with 0.1 M hydrochloric
acid or 0.1 M sodium hydroxide for alkaline and acidic
degradation respectively. The steps were completed as
described under “General procedure”. Log a/a-x versus
time (minutes) was plotted to get the reaction rate con-
stant and the half life time t1/2.
Results and discussion
Ebastine forms a highly fluorescent reaction product
upon reaction with citric acid anhydride (Figure 2).
Citric acid anhydride is proposed to condense with
ebastine producing an internal salt. The high pKa value
of EBS [33] indicates that the rate of condensation reac-
tion is dependent on the basicity of the tetriary amine.
The fluorophore was formed instantaneously and
remained stable for more than 90 minutes.
Ebastine and eosin Y react to form a complex that
resulted in eosin Y fluorescence quenching. The maxi-
mum quenching wavelength was at 553 nm (Figure 3);
this property was further extended to determine ebas-
tine in presence of its degradation products. Figures 4a-
c illustrate the fluorescence spectra of the alkaline,
acidic and UV degradation products of ebastine
respectively with corresponding lem/lex of (602/473 nm,
576/474 nm and 561/472 nm).
It is necessary to record first the normal synchronous
fluorescence spectra of EBS in presence of its different
degradation products to derive the first and second-
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Figure 2 Fluorescence spectra of the EBS (1 μg/ml) - mixed
anhydride condensation reaction product: Where A and B are
the excitation and emission spectra respectively.
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Figure 3 Fluorescence spectra of the reaction product of EBS
with eosin where: A and B are the excitation and emission spectra
respectively of eosin. A’ and B’ are excitation and emission spectra
respectively of eosin after addition of 0.15 μg/ml ebastine.
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Page 4 of 14derivative synchronous spectra. The synchronous fluores-
cence spectra of EBS were recorded at 457 nm in pre-
sence of its alkaline, acidic and UV degradation products
(Figures 5a-c) respectively. There is a great overlap of the
spectra of the drug and its degradation products in
normal synchronous spectroscopy; this encouraged us to
perform first and second derivative synchronous fluores-
cence spectroscopy technique (FDSFS&SDSFS) without
prior extraction or separation step.
The fluorescence spectra of EBS and its different
degradation products were separated entirely using
FDSFS and SDSFS with a zero crossing technique of
measurement. First and second derivative synchro-
nous fluorescence spectra of EBS in presence of its
alkaline degradation product (Figures 6a-b) show that
ebastine could be separated at 421, 453 nm respec-
tively. Similarly, entire separation of EBS in presence
of its acidic degradation product was achieved at 431
and 419 nm using first and second derivative techni-
ques respectively as shown in Figures 7a-b. While the
FDSFS and SDSFS of the studied drug in the presence
of its UV degradation product (Figures 8a-b) show
that EBS could be determined at 437 and 458 nm
respectively.
Optimization of the reaction conditions for Method I
The spectrofluorimetric properties of the formed fluoro-
phore as well as the different experimental parameters
affecting development and stability of the reaction product
were carefully studied and optimized. Such factors were
changed individually while the others were kept constant.
Effect of volume of citric anhydride
Keeping all the variables constant, it was found that
increasing the volume of supersaturated solution of
CAA resulted in a gradual increase in the relative fluor-
escence intensity of the reaction product up to 5 ml,
after which it remained constant, therefore, 5.5 ± 0.5 ml
was chosen for the study (Figure 9).
Effect of reaction temperature
The effect of reaction temperature was also studied
keeping all the variables constant. The fluorescence
intensity increased remarkably by increasing the tem-
perature from 60 to 100°C. Maximum fluorescence
intensities were obtained through boiling of the reaction
mixture. Hence, the reaction was carried out in a boiling
water bath (Figure 10).
Effect of boiling time
It was found that increasing the time of boiling of the
reaction mixture resulted in a gradual increase in the
relative fluorescence intensity up to 30 minutes and
remained constant till 40 minutes, after which it
decreased gradually, therefore 35 ± 5 minutes of boiling
was used during this approach (Figure 11).
Effect of different diluting solvents
Different diluting solvents were tested to choose the
most suitable one for the formation of the reaction pro-
duct, the investigated solvents included: water, metha-
nol, acetonitrile, dimethylsulfoxide, dimethylformamide,
and acetone. The highest fluorescence intensities were
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Figure 4 Fluorescence spectra of the degradation products of EBS
through its reaction with eosin. Where A and B are the excitation
and emission spectra respectively of eosin. A’ and B’ are excitation and
emission spectra respectively of: 4a) Alkaline degradation product. 4b)
Acidic degradation product. 4c) UV degradation product.
Ibrahim et al. Chemistry Central Journal 2011, 5:11
http://journal.chemistrycentral.com/content/5/1/11
Page 5 of 14200.0 250 300 350 400 450 500 550.0
0.5
50
100
150
200
250
266.4
nm
 
 
200.0 250 300 350 400 450 500 550 600 650 694.5
0.2
20
40
60
80
100
120
140
156.4
nm
 
  
350.0 400 450 500 550 600 650 694.5
1.0
20
40
60
80
100
120
140
156.4
nm
 
b  c  a 
Figure 5 Synchronous fluorescence spectra of EBS at 457 nm in presence of: a) Alkaline degradation product. b) Acidic degradation
product. c) UV degradation product.
200.0 250 300 350 400 450 500 550 600 650 694.5
-64.8
-50
-40
-30
-20
-10
0
10
20
30
39.4
nm
D1 
 
375.0 400 450 500 550 600 650 694.5
-27.4
-20
-10
0
10
20.0
nm
D2 
a  b 
Figure 6 First and second derivative synchronous fluorescence spectra of EBS in presence of its alkaline degradation product. a) FDSFS
of EBS at 421 nm in presence of its alkaline degradation product. b) SDSFS of EBS at 453nm in presence of its alkaline degradation product.
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Figure 7 First and second derivative synchronous fluorescence spectra of EBS in presence of its acidic degradation product. a: FDSFS
of EBS at 431 nm in presence of its acidic degradation product. b: SDSFS of EBS at 419 nm in presence of its acidic degradation product.
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Figure 8 First and second derivative synchronous fluorescence spectra of EBS in presence of its UV degradation product.a )F D S F So f
EBS at 437 nm in presence of its UV degradation product. b) SDSFS of EBS at 458 nm in presence of its UV degradation product.
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Page 6 of 14achieved upon using water. Moreover, its choice adds
another advantage to the method. The results are
demonstrated in Table 1.
Optimization of the reaction conditions for Method IIA
Effect of buffer pH
The effect of mcliavain buffer pH on the fluorescence
quenching of eosin through its reaction with ebastine
was studied over pH range of 2-8 keeping all the variables
constant. It was found that maximum ΔF was obtained at
pH value of 2-2.5, after which gradual decrease in ΔF was
observed by increasing pH value (Figure 12), hence
mcliavain buffer of pH 2.2 was used in this study.
Effect of buffer volume
The effect of mcliavain buffer volume (pH 2.2) on the
fluorescence quenching was also investigated. Gradual
increase in ΔF values was obtained by increasing the
volume of the buffer up to 2 ml, after which, the ΔFv a l u e s
remained constant (Figure 13). Therefore, 2.5 ml of mclia-
vain buffer pH 2.2 was used throughout this method.
Effect of different diluting solvents
Different diluting solvents were tested to choose the
most suitable one for maximum fluorescence quenching.
The highest ΔF values were achieved upon using water.
The results are demonstrated in Table 1.
Optimization of the reaction conditions for Method IIB
The same reaction conditions concerning method IIA
were applied; in addition effect of Δ l was also investi-
gated as follows:
Selection of optimum Δ l
The synchronous fluorescence spectra of EBS in pre-
sence of its different degradation products were
recorded using different Δ l. The optimum Δ l value is
very important for performing the synchronous fluores-
cence scanning technique concerning resolution, sensi-
tivity, and features. It can directly influence spectral
shape, bandwidth, and signal value. For this reason, a
wide range of Δ l (40, 60, 80, 100, and 120 nm) was
examined. Therefore, Δ l of 100, 60 or 40 nm were
chosen as optimal for separation of EBS in presence of
its alkaline, acidic or UV degradation products respec-
tively, since it resulted in distinct well separated peaks,
with good shape, and highest SFI values.
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Figure 9 Effect of volume of CAA on the fluorescence intensity
of the formed reaction product (EBS = 1 μg/ml).
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Figure 10 Effect of reaction temperature on the fluorescence
intensity of the formed reaction product (EBS = 1 μg/ml).
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Figure 11 Effect of boiling time on the fluorescence intensity
of the formed reaction product (EBS = 1 μg/ml).
Table 1 Effect of different diluting solvents on the
fluorescence intensity (method I) or ΔF (method IIA)
Diluting solvent Proposed method
Method I Method IIA
Water 700 690
Methanol 684 450
Acetonitrile 412 430
Dioxane 304 389
Dimethylformamide 122 230
Acetone 30 150
Ebastine = 1 μg/ml.
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The relative fluorescence intensity, ΔF, or peak ampli-
tude (by FDSFS and SDSFS) - concentration plots for
ebastine by method I, method IIA, and method II B
respectively were linear over the concentration ranges
cited in Tables 2 and 3. The linearity of the calibration
curves is validated by the high value of the correlation
coefficient and value of the intercept which is close to
zero.
Sensitivity
Detection limit (LOD) is the lowest concentration of the
drug that can be detected, but not necessarily quanti-
tated, under the stated experimental conditions. The
limit of detection is generally quoted as the concentra-
tion yielding a signal-to-noise ratio of 3:1 [34] and is
confirmed by analyzing a number of samples near this
value using the following equation:
The signal − to − noise ratio s = H/h
Where H = height of the spectrum corresponding to
the drug.
h = absolute value of the largest noise fluctuation
from the baseline of the spectrum of a blank solution.
While the limit of quantification (LOQ); is the lowest
concentration of the analyte that can be determined
with acceptable precision and accuracy. It is quoted as
the concentration yielding a signal-to-noise ratio of 10:
1 and is confirmed by analyzing a number of samples
near this value [34].The calculated values are listed in
Tables 2 and 3.
Validation of the proposed methods
The proposed methods were tested for linearity, selectiv-
ity, accuracy and precision. Using the above spectro-
fluorimetric methods, linear regression equations were
obtained. The regression plots showed that there was a
linear dependence of the fluorescence intensity values,
ΔF values, or peak amplitude values on the concentra-
tion of the drug over the ranges cited in Tables 2 and 3.
The validity of the proposed methods was evaluated by
statistical analysis of the regression data regarding the
standard deviation of the residual (Sy/x), the standard
deviation of the intercept (Sa), and standard deviation of
the slope (Sb) [35]. The results are shown in Tables 2
and 3. The small values of the figures point to the low
scattering of the points around the calibration graphs
and high precision of the proposed methods.
Accuracy
The accuracy of the proposed methods was evaluated by
analyzing standard solutions of ebastine. The results
obtained by the proposed methods were favorably com-
pared with those obtained by the comparison method [3].
Statistical analysis [35] of the results obtained by the
proposed and comparison methods using student’s t-test
and variance ratio F- test, showed no significant difference
Table 2 Performance data of method I and method IIA
Parameter Value
Method
I
Method
IIA
Concentration range (μg/ml) 0.1-1.0 0.1-1.0
LOD(μg/ml) 0.026 0.021
LOQ(μg/ml) 0.066 0.042
Correlation coefficient (r) 0.9998 0.9999
Slope 0.76 0.83
Intercept -0.13 1.13
Sy/x, Standard deviation of the residuals 0.05 1.54
Sa, Standard deviation of the intercept of the
regression line
0.001 0.77
Sb, Standard deviation of the slope of the
regression line
0.03 0.002
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Figure 12 Effect of buffer pH on fluorescence quenching of
eosin by EBS (EBS = 1 μg/ml).
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Figure 13 Effect of buffer volume on fluorescence quenching
of eosin by EBS (EBS = 1 μg/ml).
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Page 8 of 14between the performance of the two methods regarding
the accuracy and precision, respectively (Tables 4, 5).
The proposed methods were evaluated by studying the
accuracy as percent relative error and precision as per-
cent relative standard deviation (RSD%); the results are
summarized in Tables 4, 5.
Precision
Repeatability The repeatability was evaluated through
analysis of different concentrations of the studied drug
in pure or in dosage forms on 4 successive times. The
mean percentage recoveries listed in Table 6 indicate
the high precision of the proposed methods.
Intermediate precision It was performed through
repeated analysis of variable concentrations of EBS
either per se or in dosage forms on four successive days.
The results are abridged in Table 6.
Robustness of the method The robustness of the meth-
ods adopted was demonstrated by the consistency of the
relative fluorescence intensity, ΔF, or peak amplitude
values with the deliberately minor changes in the experi-
mental parameters such as: volume of CAA (5.5 ±
0.5 ml), boiling time (30 ± 5 min.), buffer pH (2.2 ± 0.2)
and buffer volume (2.5 ± 0.5) which did not greatly
affect the results obtained.
Pharmaceutical applications
The proposed methods were successfully applied to the
determination of ebastine in its dosage forms. The
results are summarized in Tables 7 and 8. No interfer-
ence from the sample matrix was observed, the results
w e r ef o u n dt ob ei ng o o da g r e e m e n tw i t ht h el a b e l e d
amount.
Stability study
The proposed methods are based mainly on the reaction
between citric acid anhydride and eosin with the tertiary
amino group of ebastine. Therefore, degradation was
attained upon induced alkaline degradation using sodium
hydroxide (0.4 M for method I, 0.1 M for method II),
acidic degradation using hydrochloric acid (0.4 M, 0.1 M
for methods I and II respectively) and oxidative degrada-
tion using 3% hydrogen peroxide. Upon alkaline and acidic
Table 3 Performance data of method IIB
Parameter Alkaline degradation Acidic degradation UV degradation
First
derivative
Second
derivative
First
derivative
Second
derivative
First
derivative
Second
derivative
Concentration range (μg/ml) 0.1-1.0
LOD (μg/ml) 0.022 0.013 0.033 0.043 0.014 0.028
LOQ (μg/ml) 0.054 0.044 0.052 0.063 0.047 0.052
Correlation coefficient (r) 0.9999 0.9994 0.9999 0.9998 0.9995 0.9996
Slope 0.36 0.201 0.202 0.301 0.16 0.203
Intercept 0.89 1.18 -1.11 0.97 0.96 1.12
Sy/x, Standard deviation of the residuals 1.17 1.55 0.77 1.28 1.19 1.39
Sa, Standard deviation of the intercept of the
regression line
-0.43 -0.44 0.58 -0.34 0.74 0.68
Sb, Standard deviation of the slope of the
regression line
1.46 × 10
-3 1.94 × 10
-3 9.59 × 10
-4 1.59 × 10
-3 1.56 × 10
-3 1.82 × 10
-3
Table 4 Determination of ebastine in its pure form using method I
Parameter Amount taken (μg/ml) Amount found (μg/ml) % Recovery Comparison method
3, % Recovery
0.1 0.099 99.0 100.62
0.2 0.199 99.90 99.15
0.3 0.298 99.33 99.34
0.5 0.502 100.40
0.7 0.706 100.86
0.8 0.799 99.88
1.0 1.005 100.5
Xˉ ±S D 99.98 ± 0.66 99.70 ± 0.79
Student’s t test 0.33 (1.94)*
Variance ratio F test 1.4 (5.14)*
*Figures between parenthesis are tabulated t and F values at P = 0.05
35.
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Page 9 of 14degradation of the drug, the relative fluorescence readings
or ΔF values decreased gradually with time, thus indicating
that the proposed methods are stability indicating ones.
However, the proposed methods did not indicate the per-
oxide degradation of ebastine, and this may be due to the
formation of the N-oxide derivative of the drug which is
not susceptible to react with either CAA or eosin owing to
the blocking of the tertiary amino group.
Both alkaline and acidic degradation were found to be
temperature dependant as presented by the acidic degra-
dation for method I (Figure 14). The first order
degradation rate constant and the half life time at each
temperature were calculated (Table 9). Plotting log Kobs
values versus 1/T, the Arhenius plots were obtained and
exemplified by Figure 15. The activation energy for each
type of degradation was also calculated.
Upon exposure of methanolic solution of the con-
cerned drug to Deuterium lamp with a wavelength of
254 nm at a distance of 15 cm in a cabinet for different
time intervals, and then the studied methods were
applied, it was found that EBS decomposed by 22,19%
applying method I and method II respectively.
Table 5 Determination of ebastine in its pure form using method IIB
Parameter Amount taken
(μg/ml)
Amount found
(μg/ml)
%Recovery Comparison
method
3
Ebastine in presence of its alkaline
degradation product
SFS FDSFS SDSFS SFS FDSFS SDSFS %Recovery
0.1 0.099 0.101 0.1003 99.11 100.82 100.33 100.62
0.2 0.198 0.201 0.201 99.22 100.53 100.45 99.15
0.3 0.301 0.298 0.301 100.33 99.33 100.27 99.34
0.5 0.498 0.503 0.495 99.62 100.62 99.05
0.7 0.704 0.694 0.706 100.57 99.14 100.86
0.8 0.806 0.793 0.795 100.75 99.13 99.38
1.0 0.994 1.01 0.999 99.46 100.92 99.93
X¯ ± SD 99.87 ± 0.67 100.07 ± 0.83 100.04 ± 0.63 99.70 ± 0.79
Student’s t test 0.96 (1.94) 0.94 (1.94) 0.78 (1.94)
Variance ratio F test 1.39 (5.14) 1.1 (5.14) 1.57 (5.14)
Ebastine in presence of its acidic
degradation product
0.1 0.099 0.101 0.099 99.15 100.62 99.44 100.62
0.2 0.201 0.198 0.201 100.62 99.34 100.23 99.15
0.3 0.301 0.299 0.302 100.37 99.72 100.67 99.34
0.5 0.499 0.502 0.501 99.72 100.33 100.15
0.7 0.697 0.704 0.698 99.63 100.66 99.77
0.8 0.807 0.796 0.799 100.84 99.46 99.81
1.0 0.1003 0.1003 0.995 100.25 100.27 99.47
X¯ ± SD 100.08 ±
0.61
100.06 ± 0.54 99.93 ± 0.44 99.70 ± 0.79
Student’s t test 0.36 (1.94) 0.36 (1.94) 0.39 (1.94)
Variance ratio F test 1.68 (5.14) 2.14 (5.14) 3.22 (5.14)
Ebastine in presence of its UV
degradation product
0.1 0.1001 0.099 0.101 100.12 99.77 100.73 100.62
0.2 0.201 0.201 0.201 100.64 100.52 100.44 99.15
0.3 0.299 0.302 0.301 99.87 100.67 100.21 99.34
0.5 0.497 0.497 0.496 99.47 99.28 99.22
0.7 0.694 0.698 0.695 99.19 99.73 99.34
0.8 0.803 0.805 0.797 100.32 100.66 99.64
1.0 1.006 1.005 1.003 100.55 100.49 100.29
X¯ ± SD 100.02 ±
0.54
100.16 ± 0.56 99.98 ± 0.58 99.70 ± 0.79
Student’s t test 0.94 (1.94) 0.42 (1.94) 0.44 (1.94)
Variance ratio F test 2.14 (5.14) 1.99 (5.14) 1.86 (5.14)
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Page 10 of 14Table 6 Validation of the proposed methods for the determination o0f ebastine in pure and dosage forms
Preparation Repeatability,% Found Intermediate precision, % Found
Method I Method II Method I Method II
Ebastine pure form Ebastine (0.5 μg/ml) Ebastine (0.1 μg/ml) Ebastine (0.3 μg/ml) Ebastine (0.7 μg/ml)
99.62 100.25 100.66 99.54
99.24 100.65 100.06 99.35
100.65 100.87 100.97 100.15
100.25 99.95 99.86 99.42
Xˉ ±S D 99.94 ± 0.63 100.43 ± 0.41 100.39 ± 0.52 99.62 ± 0.37
Bastab
® tablets containing 20 mg ebastine/tablet Ebastine (0.8 μg/ml) Ebastine (0.3 μg/ml) Ebastine (0.1 μg/ml) Ebastine (0.5 μg/ml)
100.12 100.65 100.45 99.12
100.36 100.22 100.68 99.54
99.21 99.87 99.06 99.35
99.85 99.54 99.54 100.24
Xˉ ±S D 99.89 ± 0.61 100.07 ± 0.48 99.93 ± 0.76 99.56 ± 0.48
Evastine
® syrup containing 5 mg Ebastine/5ml Ebastine (1.0 μg/ml) Ebastine (0.4 μg/ml) Ebastine (0.2 μg/ml) Ebastine (0.6 μg/ml)
100.98 100.65 100.54 99.65
100.45 100.15 100.98 99.15
99.32 100.98 99.48 100.54
99.15 100.11 99.72 100.32
Xˉ ±S D 99.98 ± 0.88 100.47 ± 0.42 100.18 ± 0.7 99.92 ± 0.64
Table 7 Determination of ebastine in its dosage forms using method I
Parameter Amount taken
(μg/ml)
Amount found
(μg/ml)
% Recovery Comparison method
3,% Recovery
Bastab
® tablets containing 20 mg
ebastine/tablet
0.1 0.099 99.71 99.23
0.2 0.199 99.52 99.61
0.3 0.301 100.33 100.61
0.5 0.503 100.62
0.6 0.602 100.33
0.8 0.798 99.75
1.0 1.01 100.64
Xˉ ±S D 100.13 ± 0.46 99.82 ± 0.71
Student’s t test 0.27 (1.94)*
F test 2.38 (5.14)*
Evastine
® syrup containing
5 mg ebastine/5ml
0.1 0.101 100.96 100.12
0.2 0.201 100.55 99.61
0.3 0.301 100.33 99.51
0.5 0.499 99.81
0.6 0.598 99.67
0.8 0.801 100.13
1.0 1.01 100.93
Xˉ ±S D 100.34 ± 0.51 99.75 ± 0.33
Student’s t test 0.34 (1.94)*
F test 2.39 (5.14)*
*Figures between parenthesis are tabulated t and F values at P = 0.05
35.
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Page 11 of 14Table 8 Determination of ebastine in its dosage forms by SFS using method IIB
Proposed method Comparison method
3
Preparation Amount found (μg/ml) Amount found (μg/ml) %Recovery %Recovery
Bastab
® tablets containing 20 mg ebastine/tablet 0.1 0.099 99.28 99.23
0.3 0.299 99.84 99.61
0.5 0.503 100.66 100.61
0.7 0.703 100.43
0.9 0.903 100.39
1.0 0.998 99.77
X¯ ± SD 100.06 ± 0.52 99.82 ± 0.71
Student’s t test 0.35 (2.31)*
Variance ratio F test 1.86 (5.79)*
Evastine
® syrup containing 5 mg ebastine/5ml 0.1 0.1001 100.06 100.12
0.3 0.298 99.64 99.61
0.5 0.499 99.87 99.51
0.7 0.704 100.59
0.9 0.901 100.11
1.0 1.007 100.74
X¯ ± SD 100.17 ± 0.42 99.75 ± 0.33
Student’s t test 0.24 (2.31)*
Variance ratio F test 1.62 (5.79)*
*Figures between parenthesis are tabulated t and F values at P = 0.05
35.
Table 9 Kinetic parameters for acidic and alkaline degradation of ebastine using the proposed methods
Temperature (°C) Method I Method II
Alkaline degradation Acidic degradation Alkaline degradation Acidic degradation
K (min.
-1)t 1/2 (min.) K (min.
-1)t 1/2 (min.) K (min.
-1)t 1/2 (min.) K (min.
-1)t 1/2 (min.)
50 1.06 × 10
-2 65 1.3 × 10
-2 52 1.06 × 10
-2 65 1.3 × 10
-2 52
60 0.94 × 10
-2 74 1.2 × 10
-2 58 0.94 × 10
-2 74 1.2 × 10
-2 58
70 0.89 × 10
-2 77 1.1 × 10
-2 62 0.89 × 10
-2 77 1.1 × 10
-2 62
80 0.81 × 10
-2 86 1.03 × 10
-2 67 0.81 × 10
-2 86 1.03 × 10
-2 67
Ea = (Joule/mol) 7.1 6.8 6.9 7.2
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Figure 14 Semilogarithmic plot of EBS (500 ng/ml) versus
different heating times with 0.4 M HCl. (A = 80°C, B = 70°C, C =
60°C, and D = 50°C).
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Figure 15 Arrhenius plot for the degradation of EBS using
method I. Where: A: (acidic degradation), B: (alkaline degradation).
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Page 12 of 14Mechanism of the reaction
The stoichiometry of the reaction between ebastine and
citric acid anhydride was studied using limiting logarith-
m i cm e t h o d[ 3 6 ] .A ss h o w ni nF i g u r e1 6 ,ap l o to fl o g
RFI versus log [CAA] and log [ebastine] gave straight
lines. The values of the slopes were 0.85 and 1.015
respectively; pointing out that the drug reacts with the
fluorigenic reagent in a ratio of 1:1. By analogy to a pre-
vious study [37], the reaction pathway is proposed to
proceed as shown in scheme 1.Scheme 1
Proposal of the reaction pathway between EBS
and CAA.
Conclusion
Two validated stability indicating spectrofluorimetric
methods were developed for the determination of ebas-
tine (EBS) in pharmaceutical preparations depending
on reaction with its tertiary amino group. The simpli-
city, low cost, and sensitivity of the proposed methods
allow their use in quality control laboratories for rou-
tine work.
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